This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Iovance Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
IOVA is poised for a Q3 earnings beat as Amtagvi sales drive revenue, Proleukin adds growth and pipeline progress draws investor attention.
IOVANegative Net Change PFEPositive Net Change MRKPositive Net Change AMRXNegative Net Change
biotechs earnings medical pharmaceuticals
Buy Moderna Stock Before Q3 Earnings? Here's What to Know
by Sundeep Ganoria
MRNA's Q3 earnings are expected to arrive amid a 652% stock rally, premium valuation and promising cancer therapy data. Should investors buy, sell or hold?
MRNAPositive Net Change GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?
by Zacks Equity Research
PGEN's Q3 results hinge on Papzimeos sales momentum and pipeline updates as competitive threat grows from a newly approved RRP therapy.
PGENNegative Net Change PFEPositive Net Change INONegative Net Change AMRXNegative Net Change
biotechs
Novo Before Q3 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO faces intensifying GLP-1 competition, earnings cuts and pricing pressure, challenging its growth outlook ahead of Q3 results.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers Squibb gains 3% after beating third-quarter estimates, as its Growth Portfolio and promising pipeline support revenue prospects despite generic competition.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
by Zacks Equity Research
Regeneron's Q3 earnings and revenues beat estimates, fueled by strong Dupixent profits, Eylea HD growth and robust Libtayo demand. Stock up.
REGNNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS View
by Zacks Equity Research
AbbVie beats Q3 earnings and revenue estimates as strong immunology and neuroscience sales drive growth, prompting a higher 2026 EPS outlook.
ABBVPositive Net Change RHHBYPositive Net Change JNJPositive Net Change
biotechs earnings medical pharmaceuticals
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
by Sundeep Ganoria
Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.
VKTXPositive Net Change NVOPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth
by Zacks Equity Research
Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.
GILDPositive Net Change TGTXPositive Net Change IOVANegative Net Change AMRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns
by Zacks Equity Research
Alnylam's shares fall 25% despite Q3 beat as slower Amvuttra patient starts and demand concerns weigh on investor sentiment.
ALNYPositive Net Change REGNNegative Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs medical pharmaceuticals